High and rising clinical development costs, coupled with declining drug discovery success rates and slowing corporate earnings growth have forced pharmaceutical companies to re-evaluate their drug development process in order to reduce attrition rates, shorten drug development timescales and remain competitive.

Over the next decade biomarkers are expected to radically alter the way in which pharmaceutical companies determine the economic viability of their drug discovery process. The use of biomarkers to aid the discovery of promising products will:

• Create an enhanced understanding of the clinical development process and
• Help to facilitate the shift towards 'personalised’ medicine

InVenio™ Technology will be a key tool that enables pharmaceutical and biotechnology companies to:

1.  Make a step change in the discovery of novel drug targets – The identification of new protein biomarkers may be the entry point for new drug discovery programmes:

• a protein biomarker may present a target for a new drug entity to be created to impact upon progress of a disease;

• unravelling the biochemistry behind the particular levels of protein biomarkers can provide significant insight into the underlying mechanisms of the disease process and allow scientists to intervene with a therapeutic drug at the correct point in the disease’s progression.